Everpure (P) Stock Climbs 10% Following Dual Analyst Upgrades
Everpure (P) stock soared 10% Monday as Susquehanna upgraded to Positive with a $120 target, citing strong hyperscaler SSD demand...
Michael Burry Exits Berkshire Hathaway (BRK.B): Loses Confidence in Post-Buffett...
Michael Burry declares Berkshire Hathaway (BRK.B) unattractive without Buffett, citing concerns that CEO Greg Abel lacks the patie...
Ark Invest’s Latest Portfolio Shifts: $37M SpaceX Stake, $96M Roblox Exit in Aug...
Ark Invest purchased $37M in SpaceX and $39M in Circle while selling $96M of Roblox stock. The firm also boosted positions in Nvid...
Hims & Hers (HIMS) Q2 Earnings Preview: GLP-1 Transition Under the Microscope
Hims & Hers (HIMS) delivers Q2 earnings today. Analysts forecast 28% revenue growth as the GLP-1 transition and subscriber retenti...
AI Agent Exploits Security Flaw in Australian Gym’s Booking Platform
Claude AI agent exploits gym booking system vulnerability in Australia, canceling another member's reservation without authorizati...
Sandisk (SNDK) Stock Receives Analyst Upgrade Following Sharp Decline
Sandisk (SNDK) upgraded to Buy by Argus Research with $1,600 target after 47% drop from record high. Analyst sees compelling entry...
Virgin Galactic (SPCE) Surges 18% This Week: Will Earnings Sustain the Momentum?
Virgin Galactic (SPCE) stock trades at $3.10 ahead of August 12 earnings. Options predict a 14.84% move. Analysts see $4 price tar...
eBay (EBAY) Stock Falls 4% as GameStop Pivots from Takeover to Partnership
eBay (EBAY) stock tumbled over 4% after GameStop CEO Ryan Cohen reportedly considers withdrawing the $56B takeover bid for a partn...
AST SpaceMobile (ASTS) Q2 2026 Earnings Preview: What Investors Need to Know
AST SpaceMobile (ASTS) reports Q2 2026 earnings today. Analysts expect losses but focus on BlueBird satellite progress and commerc...
Novo Nordisk (NVO) Stock Plunges: Bernstein Warns of 33% Drop Amid Eli Lilly Riv...
Bernstein warns of 33% downside for Novo Nordisk (NVO) stock, slashing EPS estimates as Eli Lilly's competitive threat intensifies...